Pulmonx/LUNG

$10.12

-2.59%
-
1D1W1MYTD1YMAX

About Pulmonx

Pulmonx Corporation is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions include Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), which is designed to treat emphysema patients. The Zephyr Valve, Chartis System and StratX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The StratX Platform is a cloud-based quantitative computerized tomography (CT) analysis service that provides physicians with an easy-to-read report that it has designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves.

Ticker

LUNG

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Glendon French

Employees

269

Headquarters

Redwood city, United States

Pulmonx Metrics

BasicAdvanced
$414.11M
Market cap
-
P/E ratio
-$1.60
EPS
0.65
Beta
-
Dividend rate

What the Analysts think about Pulmonx

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
63.04% upside
High $18.00
Low $14.00
$10.12
Current price
$16.50
Average price target

Pulmonx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-71.87% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$19.2M
9.09%
Net income
$-13.8M
-7.38%
Profit margin
-71.87%
-15.1%

Pulmonx Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.42
-$0.43
-$0.39
-
Expected
-$0.44
-$0.44
-$0.43
-$0.46
Surprise
-4.55%
-1.56%
-8.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Pulmonx stock

Buy or sell Pulmonx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing